Principal Financial Group Inc. Has $7.29 Million Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Principal Financial Group Inc. increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 18.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 401,432 shares of the life sciences company’s stock after purchasing an additional 63,266 shares during the quarter. Principal Financial Group Inc. owned approximately 0.52% of Integra LifeSciences worth $7,294,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after acquiring an additional 1,621,655 shares during the period. Cooke & Bieler LP grew its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after purchasing an additional 388,710 shares during the period. Dimensional Fund Advisors LP increased its stake in Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after purchasing an additional 12,766 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Integra LifeSciences by 90.9% during the 2nd quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company’s stock worth $17,436,000 after purchasing an additional 291,326 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Trading Up 1.7 %

Shares of Integra LifeSciences stock opened at $22.88 on Wednesday. The company’s 50-day moving average price is $19.74 and its 200-day moving average price is $24.05. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -254.22, a PEG ratio of 0.78 and a beta of 1.08. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the company earned $0.76 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. On average, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Bank of America decreased their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. JMP Securities reduced their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $24.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.